DALLAS (May 2, 2025) – Holland & Knight advised Iris Acquisition Corp., a special purpose acquisition company backed by Arrow Capital, on the completion of its previously announced business combination with Liminatus Pharma LLC. The completed transaction was announced on April 30.
The combined company has been renamed Liminatus Pharma Inc., and its common stock and warrants will trade on the Nasdaq under the new ticker symbols "LIMN" and "LIMNW," respectively.
La Palma, California-based Liminatus is a pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies. Iris is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
Holland & Knight's representation of Iris was led by Partner Chauncey Lane and Senior Counsel Kristin Padgett, with assistance from Partners Kelsie Knight and Jeremiah Mayfield and Associates Cooper Overcash and Trysten Henderson (M&A); Partners Amy Curtis and Paul Monsour (Capital Markets); Associates David Rascoe and Samson Goriola (M&A and Capital Markets); Partners Alan Schwartz and Ross Tuminello and Associate Bryce Klein (Tax); Partner Charles Weiss (Intellectual Property); Partner Antonia Tzinova (International Trade/CFIUS); and Associate Sara Klock (Regulatory).
More information on the transaction can be found here.
Recently recognized as the Private Equity Law Firm of the Year by the Global M&A Network, Holland & Knight regularly ranks among the leading M&A and private equity law firms in reputable, benchmarking league tables published by Bloomberg, LSEG, Mergermarket, PitchBook and The Deal. Through the HK Deal Flow℠ program, Holland & Knight facilitates deal leads for clients and prospective clients by matching acquisition or capital raising opportunities with buyers and investors.